How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly populatio
Phase 1
- Conditions
- Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2016-001436-35-BE
- Lead Sponsor
- Service of Neurology, CHU Liege
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Relatively healthy late middle aged individuals (50-70 y.o.; 50% females)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 90
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
Exclusion Criteria
Body mass index (BMI) > 29; depression, anxiety, history of epilepsy, addiction and other psychiatric disorders, diabetes, and use of psychoactive drug; early signs of dementia; excessive caffeine/alcohol consumption (> 5 cups/day and > 14 units/week respectively); shift-work in the last 6 months; transmeridian travel in the past 2 months.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method